Icon PLC
ICLR: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$516.00 | Sbcwfx | Xvlclfgw |
Icon Continues to Benefit From Increased Clinical Trial Outsourcing Demand
Business Strategy and Outlook
We believe Icon possesses all the necessary elements to win share in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.